Beta-glucuronidase production

Bacteria that carry beta-glucuronidase genes are common in healthy guts. Their enzyme can help return some hormones and medicines to circulation after the liver has prepared them for excretion. This stool DNA result estimates your gut community's potential to produce that enzyme.

It's an exploratory marker. Human research connects this enzyme with hormone metabolism and drug exposure, but this production score hasn't been validated to diagnose disease, predict future illness, or guide treatment. There is no established health target for the result.

How the Enzyme Works

Your liver attaches glucuronic acid to many hormones, drugs, and other compounds, making them easier to excrete. Glucuronic acid is a sugar-derived molecule. Some tagged compounds leave through urine; others enter your intestine in bile. Beta-glucuronidase removes the tag, and bacteria can use the released sugar for food.

The freed compound may be absorbed again, changed further by microbes, or leave in stool. Reabsorption through the gut and return to the liver is called enterohepatic circulation. This process is part of normal physiology, though reactivating particular drugs or harmful compounds can cause problems. Your own cells also make beta-glucuronidase; this result concerns the production potential of your gut microbes.

Which Bacteria Make It

Many ordinary gut bacteria carry genes for this enzyme, including Bacteroides species, Escherichia coli, and Faecalibacterium prausnitzii. In a study of stool DNA from 60 healthy people, Bacteroides contributed most of the predicted enzyme-producing capacity, but the abundance and types of enzyme genes differed widely between people.

Different versions of the enzyme act on different compounds. A version that readily processes one drug may be much less effective against another. Counting enzyme-producing bacteria or their genes therefore gives an incomplete picture of what happens to a particular hormone or medicine in your gut. A higher production result doesn't establish that harmful bacteria have taken over.

Estrogen Recycling

The estrobolome is the collection of gut microbial genes involved in estrogen metabolism. Beta-glucuronidase is one part of it. Researchers have studied stool enzyme activity, microbial genes, and estrogen levels in different samples, and those measurements answer different questions.

A small study of men and postmenopausal women linked directly measured stool enzyme activity with some estrogen measures in stool and urine, but not consistently across estrogen types. The study did not measure blood hormones, and its activity assay differs from this production estimate.

A later study measured microbial genes together with estrogens in stool and plasma. Beta-glucuronidase gene abundance alone did not track total plasma estrogens. Combining it with genes for another estrogen-processing enzyme showed an association with estrogens in stool that had been freed from their tags. These findings support studying several microbial functions together; they don't establish how much estrogen your own gut returns to your blood.

PCOS and Premature Ovarian Insufficiency

These studies measured enzyme activity directly in stool, which is related to, but different from, the production potential reported here. In a study of 48 women, the group with polycystic ovary syndrome had higher average activity than controls, with substantial overlap between groups.

A separate study reported markedly lower average stool activity in women with premature ovarian insufficiency than in controls. This condition involves reduced ovarian function before age 40. Within the affected group, higher activity was associated with higher blood estradiol.

These are comparisons of people who already had a diagnosis. They don't show whether altered enzyme activity causes either condition, follows hormonal changes, or reflects other differences between the groups. They also don't establish that lowering or raising your production score would improve ovarian function.

Endometriosis and Breast Cancer

One endometriosis study found increased beta-glucuronidase expression in lesion tissue and effects on lesion growth in mice and cultured cells. Tissue expression is a different measurement from microbial production potential in stool. In a small 2026 study of women undergoing gynecologic surgery, directly measured stool enzyme activity did not differ significantly between those with ovarian endometriosis and controls with other benign ovarian conditions.

A study of postmenopausal women with newly diagnosed hormone-sensitive breast cancer found no statistically significant difference in the total proportion of bacteria classified as beta-glucuronidase producers compared with healthy controls. These studies do not establish this result as a way to detect endometriosis or assess your breast cancer risk.

Colon Cancer

Gut bacterial beta-glucuronidase can reactivate some potentially harmful compounds that have been tagged for excretion. An older study found directly measured stool enzyme activity about 1.7 times higher in people with colon cancer than in healthy controls. When the researchers broke bacterial cells open before testing, the difference was 12.1-fold. The large change with sample preparation shows why activity values from different methods cannot be treated as equivalent.

That study compared people who already had cancer. It did not test whether enzyme activity predicts future cancer, and it did not measure this DNA-based production score. This result has no established role in colorectal cancer screening.

Drugs Your Gut Can Reactivate

Irinotecan is converted in the body to an active compound called SN-38. The liver attaches glucuronic acid to SN-38, and the tagged form can enter the intestine in bile. Bacterial beta-glucuronidase can release active SN-38 again, exposing the intestinal lining and contributing to delayed diarrhea. Human studies support this mechanism, alongside laboratory and animal experiments.

Mycophenolic acid is the active compound in mycophenolate medicines used to suppress the immune system. It also undergoes enterohepatic circulation. In one study, stem cell transplant recipients had lower directly measured stool enzyme activity than kidney transplant recipients. The comparison suggests a possible contribution to differences in drug handling, but the groups also differed in treatment and clinical circumstances.

In a separate study of 20 stem cell transplant recipients receiving intravenous mycophenolate, greater recycling was associated with more of several Bacteroides species and higher drug concentrations just before the next dose. Total exposure across the dosing interval did not differ significantly. Neither study established a dosing rule based on a stool production score.

When Results Can Be Misleading

• Genes and activity are different: carrying an enzyme gene doesn't show how much enzyme a bacterium makes or how quickly it processes a particular compound.
• Enzyme versions differ: a combined production estimate can hide differences in the types of hormones and medicines that individual enzymes can process.
• Laboratory methods affect the estimate: DNA extraction, sequencing coverage, reference databases, and analysis methods can change which microbes and genes are detected. Scores from different methods or laboratories aren't interchangeable.
• Recent changes matter: antibiotics, illness, bowel preparation, and major diet changes can alter the sampled microbial community. A result obtained during those changes may not represent your usual state.
• Activity-study findings don't define this score: low stool activity has been observed in recurrent C. difficile infection, but a low production estimate alone doesn't diagnose infection or a depleted microbiome.